177 related articles for article (PubMed ID: 35847095)
1. Comparison of Anticancer Activities and Biosafety Between
Liu X; Guo Y; Sun Y; Chen Y; Tan W; Min JJ; Zheng JH
Front Microbiol; 2022; 13():914575. PubMed ID: 35847095
[No Abstract] [Full Text] [Related]
2. Engineered oncolytic bacteria HCS1 exerts high immune stimulation and safety profiles for cancer therapy.
Sun Y; Guo Y; Liu X; Liu J; Sun H; Li Z; Wen M; Jiang SN; Tan W; Zheng JH
Theranostics; 2023; 13(15):5546-5560. PubMed ID: 37908720
[No Abstract] [Full Text] [Related]
3. Complete genome sequence of Salmonella enterica serovar Typhimurium VNP20009, a strain engineered for tumor targeting.
Broadway KM; Modise T; Jensen RV; Scharf BE
J Biotechnol; 2014 Dec; 192 Pt A():177-8. PubMed ID: 25046822
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice.
Zhang Y; Zhang N; Zhao M; Hoffman RM
Oncotarget; 2015 Jun; 6(16):14625-31. PubMed ID: 25714030
[TBL] [Abstract][Full Text] [Related]
6. Effect of Salmonella enterica serovar Typhimurium VNP20009 and VNP20009 with restored chemotaxis on 4T1 mouse mammary carcinoma progression.
Coutermarsh-Ott SL; Broadway KM; Scharf BE; Allen IC
Oncotarget; 2017 May; 8(20):33601-33613. PubMed ID: 28431394
[TBL] [Abstract][Full Text] [Related]
7. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.
Clairmont C; Lee KC; Pike J; Ittensohn M; Low KB; Pawelek J; Bermudes D; Brecher SM; Margitich D; Turnier J; Li Z; Luo X; King I; Zheng LM
J Infect Dis; 2000 Jun; 181(6):1996-2002. PubMed ID: 10837181
[TBL] [Abstract][Full Text] [Related]
8. Immune response induced by ppGpp-defective Salmonella enterica serovar Gallinarum in chickens.
Park SI; Jeong JH; Choy HE; Rhee JH; Na HS; Lee TH; Her M; Cho KO; Hong Y
J Microbiol; 2010 Oct; 48(5):674-81. PubMed ID: 21046347
[TBL] [Abstract][Full Text] [Related]
9. Bacterial cancer therapy using the attenuated fowl-adapted
Lim D; Kim K; Duysak T; So E; Jeong JH; Choy HE
Mol Ther Oncolytics; 2023 Dec; 31():100745. PubMed ID: 38053546
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of VNP20009, an attenuated Salmonella, in murine tumor models.
Luo X; Li Z; Lin S; Le T; Ittensohn M; Bermudes D; Runyab JD; Shen SY; Chen J; King IC; Zheng LM
Oncol Res; 2001; 12(11-12):501-8. PubMed ID: 11939414
[TBL] [Abstract][Full Text] [Related]
11. Attenuated Salmonella VNP20009 mutant (ΔhtrA) is a promising candidate for bacteria-mediated tumour therapy in hosts with TNFR1 deficiency.
Xu W; Zhou T; Zhou J; Qiang Z; Zhang J; Hua Z
Lett Appl Microbiol; 2018 Jul; 67(1):97-103. PubMed ID: 29698572
[TBL] [Abstract][Full Text] [Related]
12. Rescuing chemotaxis of the anticancer agent Salmonella enterica serovar Typhimurium VNP20009.
Broadway KM; Denson EA; Jensen RV; Scharf BE
J Biotechnol; 2015 Oct; 211():117-20. PubMed ID: 26200833
[TBL] [Abstract][Full Text] [Related]
13. Optimizing the restored chemotactic behavior of anticancer agent Salmonella enterica serovar Typhimurium VNP20009.
Broadway KM; Suh S; Behkam B; Scharf BE
J Biotechnol; 2017 Jun; 251():76-83. PubMed ID: 28433721
[TBL] [Abstract][Full Text] [Related]
14. Immune response induced by Salmonella typhimurium defective in ppGpp synthesis.
Na HS; Kim HJ; Lee HC; Hong Y; Rhee JH; Choy HE
Vaccine; 2006 Mar; 24(12):2027-34. PubMed ID: 16356600
[TBL] [Abstract][Full Text] [Related]
15. Culture of attenuated
Ahmed SG; Oliva G; Shao M; Mekalanos JJ; Brenner GJ
Hum Vaccin Immunother; 2023 Aug; 19(2):2262639. PubMed ID: 37786375
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of acute leukemia with attenuated Salmonella typhimurium strain VNP20009.
Li M; Lu M; Lai Y; Zhang X; Li Y; Mao P; Liang Z; Mu Y; Lin Y; Zhao AZ; Zhao Z; Zhou S; Li F
Biomed Pharmacother; 2020 Sep; 129():110425. PubMed ID: 32570123
[TBL] [Abstract][Full Text] [Related]
17. Effect of Antibiotic Treatment on Attenuated
Ahmed SG; Brenner GJ
Anticancer Res; 2023 Jan; 43(1):1-6. PubMed ID: 36585175
[TBL] [Abstract][Full Text] [Related]
18. Salmonella typhimurium Suppresses Tumor Growth via the Pro-Inflammatory Cytokine Interleukin-1β.
Kim JE; Phan TX; Nguyen VH; Dinh-Vu HV; Zheng JH; Yun M; Park SG; Hong Y; Choy HE; Szardenings M; Hwang W; Park JA; Park S; Im SH; Min JJ
Theranostics; 2015; 5(12):1328-42. PubMed ID: 26516371
[TBL] [Abstract][Full Text] [Related]
19. Suppression of pancreatic ductal adenocarcinoma growth by intratumoral delivery of attenuated Salmonella typhimurium using a dual fluorescent live tracking system.
Zhou S; Zhao Z; Lin Y; Gong S; Li F; Pan J; Li X; Gao Z; Zhao AZ
Cancer Biol Ther; 2016 Jul; 17(7):732-40. PubMed ID: 27089121
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Toso JF; Gill VJ; Hwu P; Marincola FM; Restifo NP; Schwartzentruber DJ; Sherry RM; Topalian SL; Yang JC; Stock F; Freezer LJ; Morton KE; Seipp C; Haworth L; Mavroukakis S; White D; MacDonald S; Mao J; Sznol M; Rosenberg SA
J Clin Oncol; 2002 Jan; 20(1):142-52. PubMed ID: 11773163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
